ClinicalTrials.gg
Sign In

Drug

Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 clinical trials

Also written IBI363.

studies test it
17
open now
16
in phase 3
1
first study started
2022

Keep track of what changes. Save the Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

IBI363 + chemotherapy
4

Development codes

IBI363
11
IBI325
1

Combined with it in one product

IBI363+IBI305
1
IBI363 + bevacizumab
1

Studies by the year they started

17 studies that test it; most in 2026 (6)

Studies that test Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363, by start year
YearStudies
20221
20232
20244
20254
20266

By phase

A phase 1/2 study counts in both.

Phase 1
7
Phase 2
13
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Melanoma
2
Lymphoma
1
Carcinoma, Non-Small-Cell Lung
1
Colorectal Neoplasms
1
Carcinoma
1
Carcinoma, Renal Cell
1
Neoplasms
1

Who runs them

Industry 9 · Other 8

Innovent Biologics (Suzhou) Co. Ltd. (9) · Shanghai Pulmonary Hospital, Shanghai, China (2) · The First Affiliated Hospital of Zhengzhou University (1) · Ruijin Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Zhejiang Cancer Hospital (1) · Xiangdong Cheng (1) · Hunan Province Tumor Hospital (1)

Often tested with

Tested in the same studies.

Bevacizumab (3) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Izalontamab brengitecan (1) · CVL006 (1) · KXV01 (1) · MT027 (1) · QH101 (1)

Studies

Open first, then newest update. How each study uses Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 is read from its arms, and is right about nine times in ten.

Testing it · 17

Given in every arm · 1 — Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 is usual care beside what is tested